Pierre Fabre Cashes The AbCheck: Antibody Deal Expands After Initial Success
This article was originally published in The Pink Sheet Daily
Decision by France’s third-largest drug maker to make AbCheck its main provider of antibody therapies will make Affimed’s Czech biotech profitable and better able to invest in rabbits.
You may also be interested in...
PureTech said it finished 2019 with healthy finances and a promising pipeline which analysts said should offer positive catalysts for the UK group’s stock in 2020.
The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.
Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.